Analysis of the citation of evidence in traditional Chinese medicine clinical pathways_Chinese Journal of Evidence-Based Medicine

Authors：

LI Huizhen ¹ ^# , LIU Meijun ² ^# , LIANG Ning ¹ , LIU Yuqi ¹ , LIU Mengyu ¹ ,  WANG Yanping ¹ ,  SHI Nannan ¹

1. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, P.R.China;
2. Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, P.R.China;

Corresponding?author：

WANG Yanping, Email: wangyanping4816@163.com; SHI Nannan, Email: 13811839164@vip.126.com

Keywords：

Traditional Chinese medicine; Clinical pathway; Evidence-based medicine; Citation of evidence

DOI：

10.7507/1672-2531.201909043

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To analyze the citation of evidence in traditional Chinese medicine (TCM) clinical pathways in China, and to provide suggestions for future development and revision of TCM clinical pathways.Methods TCM clinical pathways released on the websites of national administration of TCM and China association of Chinese medicine were obtained, with the retrieval time limit to June 2019. Two researchers separately utilized the Excel to extract data and performed a descriptive analysis.Results A total of 405 TCM clinical pathways were included, involving internal medicine, surgery, gynecology and pediatrics. Internal medicine accounted for the largest proportion of the TCM clinical pathways (133). All the 405 pathways cited references as evidence, among which the maximum and minimum quantities of cited references were 11 and 1, respectively, and the median was 3. More than 90% of the TCM clinical pathways cited the evidence in the parts of diagnosis and efficacy evaluation. For parts of TCM and western medicine treatment, the proportion of TCM clinical pathways which cited evidence was less than 75%; for parts of rehabilitation and nursing, the proportion of TCM clinical pathways which cited evidence was less than 2%. The types of evidence being cited were standard indicators (683), clinical practice guidelines (488), textbooks (236), consensus opinions, ancient books and clinical surveys. The released time was reported in 89.25% of the cited evidence; the largest time interval was between the release time of the standard indicators (evidence) and that of the TCM pathways. Among the evidence released more than 15 years before the release of the TCM pathways, the proportion of standard indicators was the highest (57.12%).Conclusions The published TCM clinical pathways are all developed based on evidence, however, the evidence citation ratio in different parts varies greatly. In some TCM clinical pathways, the cited evidences are not reported normatively, and some evidence are poor in timeliness.

Citation： LI Huizhen, LIU Meijun, LIANG Ning, LIU Yuqi, LIU Mengyu, WANG Yanping, SHI Nannan. Analysis of the citation of evidence in traditional Chinese medicine clinical pathways. Chinese Journal of Evidence-Based Medicine, 2020, 20(3): 306-310. doi: 10.7507/1672-2531.201909043 Copy

1.	楊華先. 中醫臨床路徑特點分析與實施思考. 智慧健康, 2018, 4(27): 143-144, 146.
2.	楊惠英, 劉麗敏, 于秋濱, 等. 臨床路徑設計的關鍵環節與執行障礙因素研究. 重慶醫學, 2013, 42(7): 829-830.
3.	黃先濤. 臨床路徑管理的發展與現狀. 中國病案, 2014, 15(11): 22-24.
4.	鄒婧瑜, 蘇維. 臨床路徑的發展與應用現狀. 現代預防醫學, 2008, 35(23): 4610-4612.
5.	葉健文. 基于臨床路徑中醫單病種付費標準測算探析. 財經界, 2019, (11): 93-95.
6.	呂麗. 基于臨床路徑按病種付費之績效分配初探. 財經界(學術版), 2019, (2): 151-152.
7.	李風娟. 分析臨床路徑控制醫療費用的原因. 中國市場, 2019, (31): 104-105.
8.	姚偉平, 劉旺華, 李花, 等. 中醫主訴診療學對中醫臨床路徑制定的指導意義. 中醫雜志, 2019, 60(12): 1074-1076.
9.	王忠云, 趙青松. 臨床路徑實施經驗介紹. 中國護理管理, 2011, 11(7): 10-11.
10.	馮浩. 臨床路徑的基本概念及其應用. 臨床醫藥文獻電子雜志, 2016, 3(49): 9871, 9873.
11.	鄧玉宏, 王忠, 馬利, 等. 實施臨床路徑的意義及其應用現狀. 現代生物醫學進展, 2010, 10(9): 1756-1759.
12.	王思成, 韓梅, 劉建平. 臨床路徑概要及中醫臨床應用思路. 中國中西醫結合雜志, 2009, 29(12): 1064-1067.
13.	王思成, 劉建平, 李慧, 等. 循證中醫臨床路徑的報告規范. 中西醫結合學報, 2010, 8(9): 819-823.
14.	王民秀. 青風內障(青光眼)中醫臨床路徑制定初探. 全國第九次中醫, 中西醫結合眼科學術年會論文匯編, 2010: 110-114.
15.	劉建平. 循證醫學(第 2 版). 北京: 人民衛生出版社, 2018: 87.
16.	張愛武, 唐紅, 羅曉勘. 臨床路徑與循證醫學相關性初探. 中國衛生事業管理, 2011, 28(9): 678-679, 717.
17.	畢齊, 宋哲. 循證醫學與臨床路. 中醫雜志, 2010, 51(S1): 6-7.
18.	王麗, 江啟成. 循證醫學與臨床路徑. 中國衛生事業管理, 2004, 20(7): 437-438.
19.	劉建平, 王思成, 吳大嶸, 等. 循證中醫臨床路徑的制訂與實施. 中國中西醫結合雜志, 2011, 31(1): 115-119.
20.	趙風玲, 王慧娟, 李潔雅, 等. 以循證醫學為依據的慢性鉛中毒臨床路徑制訂初探. 醫藥論壇雜志, 2016, 37(4): 4-7.

1. 楊華先. 中醫臨床路徑特點分析與實施思考. 智慧健康, 2018, 4(27): 143-144, 146.
2. 楊惠英, 劉麗敏, 于秋濱, 等. 臨床路徑設計的關鍵環節與執行障礙因素研究. 重慶醫學, 2013, 42(7): 829-830.
3. 黃先濤. 臨床路徑管理的發展與現狀. 中國病案, 2014, 15(11): 22-24.
4. 鄒婧瑜, 蘇維. 臨床路徑的發展與應用現狀. 現代預防醫學, 2008, 35(23): 4610-4612.
5. 葉健文. 基于臨床路徑中醫單病種付費標準測算探析. 財經界, 2019, (11): 93-95.
6. 呂麗. 基于臨床路徑按病種付費之績效分配初探. 財經界(學術版), 2019, (2): 151-152.
7. 李風娟. 分析臨床路徑控制醫療費用的原因. 中國市場, 2019, (31): 104-105.
8. 姚偉平, 劉旺華, 李花, 等. 中醫主訴診療學對中醫臨床路徑制定的指導意義. 中醫雜志, 2019, 60(12): 1074-1076.
9. 王忠云, 趙青松. 臨床路徑實施經驗介紹. 中國護理管理, 2011, 11(7): 10-11.
10. 馮浩. 臨床路徑的基本概念及其應用. 臨床醫藥文獻電子雜志, 2016, 3(49): 9871, 9873.
11. 鄧玉宏, 王忠, 馬利, 等. 實施臨床路徑的意義及其應用現狀. 現代生物醫學進展, 2010, 10(9): 1756-1759.
12. 王思成, 韓梅, 劉建平. 臨床路徑概要及中醫臨床應用思路. 中國中西醫結合雜志, 2009, 29(12): 1064-1067.
13. 王思成, 劉建平, 李慧, 等. 循證中醫臨床路徑的報告規范. 中西醫結合學報, 2010, 8(9): 819-823.
14. 王民秀. 青風內障(青光眼)中醫臨床路徑制定初探. 全國第九次中醫, 中西醫結合眼科學術年會論文匯編, 2010: 110-114.
15. 劉建平. 循證醫學(第 2 版). 北京: 人民衛生出版社, 2018: 87.
16. 張愛武, 唐紅, 羅曉勘. 臨床路徑與循證醫學相關性初探. 中國衛生事業管理, 2011, 28(9): 678-679, 717.
17. 畢齊, 宋哲. 循證醫學與臨床路. 中醫雜志, 2010, 51(S1): 6-7.
18. 王麗, 江啟成. 循證醫學與臨床路徑. 中國衛生事業管理, 2004, 20(7): 437-438.
19. 劉建平, 王思成, 吳大嶸, 等. 循證中醫臨床路徑的制訂與實施. 中國中西醫結合雜志, 2011, 31(1): 115-119.
20. 趙風玲, 王慧娟, 李潔雅, 等. 以循證醫學為依據的慢性鉛中毒臨床路徑制訂初探. 醫藥論壇雜志, 2016, 37(4): 4-7.

Chinese Journal of Evidence-Based Medicine

Analysis of the citation of evidence in traditional Chinese medicine clinical pathways

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content